Endurance Wealth Management’s Bristol-Myers Squibb BMY Stock Holding History

Endurance Wealth Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$269K	Buy	4,199 +262	+7%	+$17.6K	0.04%	165
2023 Q1	$273K	Hold	3,937	–	–	0.04%	167
2022 Q4	$283K	Buy	3,937 +12	+0.3%	+$905	0.04%	159
2022 Q3	$279K	Sell	3,925 -50	-1%	-$3.63K	0.05%	159
2022 Q2	$306K	Sell	3,975 -8	-0.2%	-$609	0.05%	159
2022 Q1	$291K	Sell	3,983 -5	-0.1%	-$336	0.04%	172
2021 Q4	$249K	Buy	3,988 +55	+1%	+$3.23K	0.03%	196
2021 Q3	$233K	Buy	3,933 +1	+0%	+$66	0.03%	205
2021 Q2	$262K	Buy	3,932 +55	+1%	+$3.59K	0.03%	195
2021 Q1	$244K	Sell	3,877 -224	-5%	-$13.9K	0.03%	199
2020 Q4	$254K	Hold	4,101	–	–	0.03%	185
2020 Q3	$247K	Sell	4,101 -373	-8%	-$22.4K	0.04%	174
2020 Q2	$263K	Buy	4,474 +1	+0%	+$60	0.04%	165
2020 Q1	$249K	Sell	4,473 -1	-0%	-$61	0.05%	158
2019 Q4	$288K	Buy	4,474 +1,301	+41%	+$74.5K	0.04%	159
2019 Q3	$161K	Buy	3,173 +2,255	+246%	+$106K	0.03%	191
2019 Q2	$42K	Buy	918 +500	+120%	+$23.3K	0.01%	280
2019 Q1	$20K	Hold	418	–	–	﹤0.01%	329
2018 Q4	$22K	Hold	418	–	–	﹤0.01%	310
2018 Q3	$26K	Hold	418	–	–	﹤0.01%	319
2018 Q2	$23K	Hold	418	–	–	﹤0.01%	331
2018 Q1	$26K	Hold	418	–	–	﹤0.01%	330
2017 Q4	$26K	Hold	418	–	–	﹤0.01%	321
2017 Q3	$27K	Buy	418 +68	+19%	+$3.97K	﹤0.01%	318
2017 Q2	$20K	Hold	350	–	–	﹤0.01%	351
2017 Q1	$19K	Hold	350	–	–	﹤0.01%	355
2016 Q4	$20K	Hold	350	–	–	﹤0.01%	334
2016 Q3	$17K	Hold	350	–	–	﹤0.01%	354
2016 Q2	$26K	Sell	350 -300	-46%	-$21.2K	﹤0.01%	307
2016 Q1	$42	Hold	650	–	–	0.01%	276
2015 Q4	$45K	Buy	650 +200	+44%	+$13.2K	0.01%	274
2015 Q3	$28K	Hold	450	–	–	﹤0.01%	318
2015 Q2	$30K	Buy	+450	New	+$29.7K	0.01%	319

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Endurance Wealth Management's BMY Position: Q2 2023 in Review

Endurance Wealth Management increased its Bristol-Myers Squibb (BMY) stake by 6.7% in Q2 2023, buying an estimated $17.6K and bringing the position to 4,199 shares worth $269K. The position accounts for 0.04% of the portfolio, ranked #165.

Endurance Wealth Management first reported a position in BMY in Q2 2015 and has held it in 33 quarters since. The position peaked at $306K in Q2 2022. 2,481 funds tracked by Wall St. Rank hold BMY as of Q2 2023.

Endurance Wealth Management held 4,199 shares of Bristol-Myers Squibb worth $269K as of Q2 2023.
Endurance Wealth Management bought 262 Bristol-Myers Squibb shares in Q2 2023, an estimated $17.6K.
Bristol-Myers Squibb made up 0.04% of Endurance Wealth Management's portfolio in Q2 2023, its #165 holding.
Endurance Wealth Management first reported a position in Bristol-Myers Squibb in Q2 2015 and has held it in 33 quarters since.
Endurance Wealth Management's Bristol-Myers Squibb position peaked at $306K in Q2 2022.
2,481 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2023.

Based on Endurance Wealth Management's 13F filing for Q2 2023, filed 9 Aug 2023.